Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EPCAM CAR-T for Liver Cancer
NCT02729493Phase 2Unknown
- Sponsor
- Sinobioway Group Co., Ltd.
- Start
- Nov 2015
- Primary completion
- Nov 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-EPCAM CAR-T in hepatocellular carcinoma (HCC), sponsored by Sinobioway Group Co., Ltd. Primary endpoint: Disease Control Rate. Status: unknown.
02
Drugs
anti-EPCAM CAR-T
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02729493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729493.